Dr.  

Andrew Blauvelt

, United States


Presentations

Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications 10 October 2019 15:50 - 16:00
KX2-391 ointment 1%, a novel Src phosphorylation and tubulin polymerisation inhibitor, for the treatment of actinic keratosis:  Results from two pivotal Phase III studies 12 October 2019 09:20 - 09:30
Efficacy of Guselkumab Versus Secukinumab in Patients With Moderate-to-Severe Plaque Psoriasis in Subgroups Defined by Previous Psoriasis Medication History: Results From the ECLIPSE Study 09 October 2019 00:00 - 00:00
Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate-to-severe plaque psoriasis: 60-week results from a randomised, double-blinded, Phase 2b extension study 09 October 2019 00:00 - 00:00

Abstracts

Efficacy of Guselkumab Versus Secukinumab in Patients With Moderate-to-Severe Plaque Psoriasis in Subgroups Defined by Previous Psoriasis Medication History: Results From the ECLIPSE Study Psoriasis More